The question in the title is deceptively simple, and it hides two very different tasks
These findings are observational and cannot establish that GLP-1 receptor agonists directly caused these outcomes
This article examines what BPC-157 is and why it remains a topic of ongoing scientific interest
It's simple, but its impact is significant
45.3% of participants on the highest dose lost 30% or more of their body weight TRIUMPH-4 knee osteoarthritis + obesity (Dec 2025) 28.7% weight loss at 68 weeks TRANSCEND-T2D-1 type 2 diabetes (Mar 19, 2026) A1C -2.0%, 16.8% weight loss at 40 weeks TRIUMPH-2 obesity with type 2 diabetes, nested OSA protocol (July 23, 2026) 20.8% weight loss at 12 mg over 80 weeks
Since endogenous antioxidant enzymes or antioxidants are responsible for most of the bodys antioxidant capacity, strategies to enhance antioxidant-enzyme interactions for disease management involve increasing antioxidant activity or inhibiting ROS release to mitigate oxidative stress